12:30 PM EDT, 05/10/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price to $199 from $211, reflecting 51.3x our 2025 EPS estimate, below PODD's five-year average forward average P/E of 164.3x given soft multiples for the peer group due to GLP-1 drugs (though we believe the current discount is overdone). We narrow our 2024 EPS forecast by $0.20 to $3.20 and our 2025 forecast by $0.20 to $3.88. PODD reported Q1 EPS of $0.73 vs. $0.23, beating the consensus view by $0.34 and exceeding our expectations on both the top line and margins. Adjusted operating margin expanded 740 basis points Y/Y due to increased scale. PODD considers the current version of the Omnipod 5, PODD's initial minimum viable product, as the market leader, and plans to expand on the model in 2024 by bringing new sensor integrations, launching the system in new geographies, and extending PODD's phone control offering. We expect manufacturing scale and scope to drive gross margin expansion over the next few years, with new efficiency gains from the Malaysia facility expansion.